[LYSA & FILO] Le LYSA s’enrichit d’une commission LLC/MW Cette évolution est issue d’une volonté collective du comité LLC/MW du #FILO d'unifier les projets autour des hémopathies lymphoïdes et de conduire ses nouveaux travaux au sein du LYSA/LYSARC. Romain Guieze Morschhauser

[LYSA Days] Presentations by Gerhard Held, Gabriel Brisou, Yassine Al Tabaa, Guillaume Cartron and Sylvain Choquet on DLBCL studies: NIVEAU, DESCART, ALYCANTE, BICAR #LYSATours24 #lymphoma

[LYSA Days] Fanny Cherblanc and Benoit T talks about REALYSA in DLBCL Thank you ! #LYSATours24 #lymphoma

Very proud to receive Prix Bertrand Coiffier and to join soon Marco Ruella lab in few weeks ! Lysa Lymphoma ELI

Very honored to have received one of the two Bertrand Coiffier 2023 Awards. Thank you very much to ELI , Lysa Lymphoma and the International Jury for awarding this prize allowing me to realize a research mobility in Prof. Davide Rossi's lab at the Institute of Oncology Research (IOR)

LYSA is pleased to announce the creation of a new scientific committee dedicated to CLL and WM! LYSA welcomes all the French CLL/WM investigators who decided to transition from FILO to LYSA for their next studies and unifying French projects related to lymphoid malignancies.

[LYSA publication Journal of Clinical Oncology] “With 6 yrFU ‘Ro-CHOP’ study still negativebut potential benefitof romidepsinin TFH-PTCL and BV+chemo at relapse“ Publication by Vincent Camus & Emmanuel Bachy ascopubs.org/doi/10.1200/JC…

[Publication LYSA dans le Journal of Clinical Oncology] « Avec un suivi de 6 ans, l’étude Ro-CHOP reste négative mais bénéfice potentiel de la romidepsine dans les PTCL-TFH et du BV+chimio en cas de rechute. » Publication de Vincent Camus & Emmanuel Bachy ascopubs.org/doi/10.1200/JC…

🤫Silence ça tourne ! On enregistre les dernières vidéos sur le parcours de leucémie lymphoïde chronique du LymphoSite.fr, la plateforme d'ℹ️ et d'éducation d'ELLyE et du Lysa Lymphoma. Thèmes d'aujourd'hui : #surveillanceactive, traitements & soins après 1 rechute #LLC

Exciting works and long-standing collaborations take birth (and renew) in meetings such as the #IELSG annual meeting, where Lysa Lymphoma was proudly represented by C. Thieblemont @marycallanan and Vincent Camus. 🙏E.Zucca franco cavalli Happy birthday Greg 🎂 !

[Publication LYSA] Interesting publication on DESCAR-T by Roch Houot in Blood Advances ! #lymphoma #descart #lysa #study

A look back at the launch of the BIDIFLY research programme in Paris on 26th March! 🔬 BIDIFLY (Biological and Imaging Data Integration for Follicular Lymphoma Research) or how artificial intelligence is revolutionising follicular lymphoma research. urls.fr/PNc3tt

Published today in Blood Journal 🎉 Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma #CART #lymsm Great collaboration with French colleagues Roch Houot Lysa Lymphoma Pere Barba pubmed.ncbi.nlm.nih.gov/38657242/

Published today in Blood Journal : "High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia" from DESCAR-T registry #CART #lymsm Work lead by Eric Durot Lysa Lymphoma, in collaboration with Dana-Farber and Columbia University pubmed.ncbi.nlm.nih.gov/38669635/

[LYSA publication NEJM] Thanks: our patients, Layla Veleanu, Laurence Lamant, the Therapeutic Strategy Project for AdultALK+ ALCL, LYSARC, NEJM, National Comprehensive Cancer Network (NCCN), INEM NECKER, @Univ_Paris, GHU APHP. Hôpitaux Universitaires Henri-Mondor, AP-HP nejm.org/doi/full/10.10…

Enticing results with brigatinib use in 15 patients with brentuximab-refractory ALK+ Anaplastic Large Cell Lymphoma from Lysa Lymphoma just out at NEJM ORR 93% CRR 73% 2 year PFS 73% 2 year OS 87% nejm.org/doi/full/10.10… #lymsm #EHA2024 #TCelllymphoma #ALCL #ALK

S241 - CAR-T in the setting of transformed indolent NHL (DESCART analysis). Comparison against matched not transformed DLBCL Better outcomes for the transformed group! 🤯 #EHA2024 Lysa Lymphoma

CAR T-cells Axi-cel in R/R PMBL A fantastic work of Lysa Lymphoma (DESCAR-T cohort) presented by the amazing Jean Galtier 👍 #EHA2024

CAR T-cells in transformed iNHL Method: PSM analysis (vs de novo DLBCL), DESCAR-T cohort CAR T-cells do well in this group, and may even do better than in de novo DLBCL ! Axi > Tisa Congrats Lysa Lymphoma and the outstanding Pierre Stephan ! #EHA2024

Responses, outcomes and safety are similar among young (<75yo) and old (≥75yo) DLBCL patients receiving CAR-T! 👴🧓 [S242 by Lysa Lymphoma ] #EHA2024 #geriheme #aging Raul Cordoba, MD, PhD